ReviewClinical reviews in allergy & immunology2020
Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
Review in Clinical reviews in allergy & immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.Allergy · 2026Guideline
- Efficacy and safety of probiotics as a complementary treatment for urticaria: a systematic review and meta-analysis.Frontiers in microbiology · 2025Pooled it
- A comprehensive analysis on the safety of two biologics dupilumab and omalizumab.Frontiers in medicine · 2024Pooled it
- Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.Dermatologic therapy · 2022Trial
- Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection.Antibodies (Basel, Switzerland) · 2026Review
- Omalizumab for Injection (Enyitan®) in Elderly Patients with Chronic Spontaneous Urticaria: Maintenance of Treatment Goals - A 6-Month Retrospective Follow-Up of Real-World Evidence.International archives of allergy and immunology · 2026Article
- Integrated Traditional Chinese and Western Medicine for Chronic Spontaneous Urticaria: Protocol for a Trials Within Cohorts Study.JMIR research protocols · 2026Article
- Omalizumab-Associated Post-Injection Urticaria Exacerbation and Urticaria-Related Adverse Reactions During Treatment for Chronic Urticaria: A Scoping Review.Life (Basel, Switzerland) · 2026Review
- Correlation between IL-17 levels and chronic urticaria: Systematic review and meta-analysis.The journal of allergy and clinical immunology. Global · 2026Article
- Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond.The journal of allergy and clinical immunology. In practice · 2026Review
- Biopredictors for Omalizumab Response in Patients With Chronic Spontaneous Urticaria.The journal of allergy and clinical immunology. In practice · 2026Article
- The effect of omalizumab treatment on inflammatory parameters in urticarial diseases: a retrospective study.Postepy dermatologii i alergologii · 2026Article
- Article
- Dual biological treatments in immune-mediated disorders: a single center experience.BMC immunology · 2025Article
- A retrospective analysis of factors influencing response to omalizumab treatment in Indian patients with antihistamine refractory chronic spontaneous urticaria.Asia Pacific allergy · 2025Article
- Histamine and TH2 cytokines regulate the biosynthesis of cysteinyl-leukotrienes and expression of their receptors in human mast cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Article
- Antihistamines and omalizumab combination treatment in patients with chronic spontaneous urticaria: Real-world experience from a tertiary care hospital.Northern clinics of Istanbul · 2025Article
- Biomarkers for Short-Term Omalizumab Response in Chronic Spontaneous Urticaria.Annals of dermatology · 2024Article
- Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5-1% of the global population. Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) is the only approved treatment for antihistamine refractory CSU. However, ~ 30% of patients remain symptomatic at licensed doses of omalizumab 150 mg and 300 mg, even after a treatment period of over 6 months. In the recent years, there have been several studies on updosing of the drug, suggesting that the individualized approach for urticaria treatment with omalizumab is useful. In this article, we provide an overview of these studies and the real-world data on omalizumab updosing as it became necessary to obtain complete CSU symptom control in a proportion of patients. Published observational studies (from June 2003 to October 2019) on the updosing of omalizumab in CSU were identified using PubMed and Ovid databases. Reports mainly show that updosing/dose adjustment evaluated with the assessment of disease activity (Urticaria Activity Score) and control (Urticaria Control Test) achieves better clinical response to omalizumab with a good safety profile in a pool of patients with CSU. These real-world data will provide an overview of updosing of omalizumab in CSU and aid in setting informed clinical practice treatment expectations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.